Our CEO Lowry Curley, PhD, had the honor of being quoted in Genetic Engineering and Biotechnology New’s July cover story. The article, written by Priya Kalia, PhD, focuses on expanding boundaries of in vitro testing with organs-on-chips systems.
“Scale-up and access to quality cells are the largest hurdles we face,” observes Lowry Curley, PhD, CEO, AxoSim. “Customers need the ability to test hundreds of times more drugs than is currently possible.”